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ABSTRACT
Epipodophyllotoxins are effective antitumour drugs
that trap eukaryotic DNA topoisomerase II in a co-
valent complex with DNA. Based on DNA cleavage
assays, the mode of interaction of these drugs was
proposed to involve amino acid residues of the cata-
lytic site. An in vitro binding study, however,
revealed two potential binding sites for etoposide
within human DNA topoisomerase IIa (htopoIIa),
one in the catalytic core of the enzyme and one in
the ATP-binding N-terminal domain. Here we have
tested how N-terminal mutations that reduce the
af®nity of the site for etoposide or ATP affect the
sensitivity of yeast cells to etoposide. Surprisingly,
when introduced into full-length enzymes, muta-
tions that lower the drug binding capacity of the
N-terminal domain in vitro render yeast more sensi-
tive to epipodophyllotoxins. Consistently, when the
htopoIIa N-terminal domain alone is overexpressed
in the presence of yeast topoII, cells become more
resistant to etoposide. Point mutations that weaken
etoposide binding eliminate this resistance pheno-
type. We argue that the N-terminal ATP-binding
pocket competes with the active site of the holo-
enzyme for binding etoposide both in cis and in
trans with different outcomes, suggesting that each
topoisomerase II monomer has two non-equivalent
drug-binding sites.
INTRODUCTION
DNA topoisomerase II (topoII) plays an essential role in the
disjunction of sister chromatids and in chromosome condensa-
tion during mitosis (for a review see 1). This nuclear protein is
strongly expressed in proliferating cells and is therefore a
useful target for antitumour agents. Both non-intercalating
topoII inhibitors, such as etoposide and teniposide, and
intercalators, such as ellipticine and amsacrine, act by trapping
the enzyme in a covalent complex with DNA (2±4) and are
widely used for the treatment of cancer. Unfortunately, high
dose chemotherapy frequently leads to drug resistance among
tumour cells. In many cases this resistance correlates with
changes in the expression (reviewed in 5±7) or primary
structure of topoII itself (4,8±10).
The identi®cation of point mutations in topoII that modify
drug sensitivity has not led to a coherent characterisation of
the drug-binding site(s), since such mutations were found
throughout the protein (11±18; for reviews see 19,20). Several
studies have mapped a ternary complex of topoII and
intercalating drugs stabilised in a covalent complex with
DNA, suggesting that the drug-binding site is near the
catalytic site (21±23). Epipodophyllotoxins and bisdioxo-
piperazine derivates do not bind DNA, however, and thus may
inhibit topoII in other ways. Recently, it was shown that the
bisdioxopiperazine ICRF-193 inhibits the ATPase activity of a
truncated form of human topoII that contains the N-terminal
domain only, supporting a direct interaction between this drug
and the ATP-binding domain (24). Using an in vitro drug-
binding assay with recombinant enzyme in the absence of
DNA, we have identi®ed at least two potential binding sites
for etoposide in human and yeast topoII (25). One, as
expected, encompasses the active site of the core enzyme
(amino acids 430±1214 of human topoIIa) and another one is
found within the N-terminal ATPase domain (amino acids 1±
440 of human topoIIa). We could show that, at low levels of
ATP, the N-terminal ATP-binding pocket binds etoposide, a
situation reminiscent of the inhibition of the bacterial
topoisomerase II gyrase B (GyrB) by the antibiotic novobiocin
(26). Structural similarities between etoposide and novobiocin
could explain this result. In the presence of DNA we suspect
that drugs may bind preferentially to the catalytic core,
because an N-terminal deleted form of the Drosophila topoII
enzyme can be trapped in the typical `cleavable' enzyme±
DNA complex induced by teniposide or ICRF-159 (27). To
reconcile these results, we propose two hypotheses: either the
two sites cooperate to create a single drug-binding pocket or
they are distinct and interact with the drug independently one
of the other, possibly under different binding conditions.
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Here we use yeast to examine in vivo the effects of
mutations that have been shown to alter the interaction of
drugs with the htopoIIa N-terminus in vitro. To characterise
the physiological relevance of the proposed N-terminus±drug
interaction, the mutations were reconstituted into the full-
length htopoIIa and expressed in a yeast strain lacking its
endogenous enzyme. All recombinant forms are stable and the
two mutants that can complement a top2 deletion in yeast
render the cells more sensitive to etoposide. Importantly, when
the N-terminal domain alone is overexpressed, the wild-type
form enhances the drug resistance of the transformed cells,
while the mutated forms do not, suggesting that the ATPase
domain of topoII can bind etoposide and modulate the effects
of antitumour drugs in vivo.
MATERIALS AND METHODS
Expression of htopoIIa and domains
The indicated point mutations in htopoIIa are described in
Leroy et al. (25). Mutations were reconstituted within full-
length htopoIIa by ligation of the MluI±EcoRI fragment of
pMalC2 and the EcoRI±CelII fragment of pHT212 (ARS-
CEN, LEU2, carrying the cDNA encoding full-length
htopoIIa fused to c-Myc and 6-His; a gift of Dr A.
Andersen) into the pHT212 backbone digested with MluI
and CelII. To express the wild-type or the mutated htopoIIa as
the unique topoII in yeast, the ClaI±SacI fragment from the
corresponding pHT212 was subcloned in pRS414 (ARS-CEN,
TRP1). This latter plasmid was used to transform the strain
GA559 (MATa, ade2-1, ura3-1, trp1-1, his3-15, leu2-3,
top2::LEU2), carrying the plasmid pBB6 (2m, URA3, TOP2).
The top2::LEU2 disruption is a null allele, removing amino
acids 161±1429. After selection of transformants on medium
lacking tryptophan, colonies were streaked on medium
containing 0.1% 5-¯uoroorotic acid (5-FOA) to force loss of
pBB6, in a process called plasmid `shuf¯ing'. Whole cell
extracts were prepared by trichloroacetic acid (TCA) pre-
cipitation or by spheroplasting cells. The pRS414 vector
carrying wild-type and mutated htopoIIa cDNAs was digested
with SmaI and SacI. The fragments were subcloned at the
®lled BamHI site and at the SacI site downstream of the GAL1
UAS in the p316 plasmid (2m, URA3). Then the htopoIIa
cDNAs were digested at EcoRI sites and blunt end-ligated
after ®lling in. This resulted in fusion of the ATPase domain
and the htopoIIa nuclear localisation signal (NLS), which
was expressed in the yeast strain GA1072 (MATa, ade2-1,
ade3-130, ura3-1, trp1-1, cyh2, pdr1::LEU2, pdr3::hisG).
The relative expression levels of the N-terminal domains
and full-length topoII forms were determined as follows.
Yeast cells (originally GA559) kept alive by the plasmid
pRS414-hTOP2 (ARS-CEN, TRP1, expressing htopoIIa)
were transformed by pRS426-Gal1-Cyc1, which carries either
wild-type or mutated forms of the topoII N-terminal domains
under the control of the GAL1 promoter. Both the wild-type
and the N-terminal forms of htopoIIa are tagged with a single
Myc epitope, allowing us to quantify their relative expression
levels with the same antibody. Cultured yeast cells were
harvested and total protein extracts were prepared by TCA
precipitation and dissolution in NaOH. Analysis of the relative
overexpression of the N-terminal domains over the wild-type
form of htopoIIa was performed by SDS±PAGE and western
blotting using 9E10 anti-Myc monoclonal, anti-pentaHis
(Qiagen), anti-yeast topoII (28) and rat anti-p42RNase H (a gift
of U. Wintersberger, University of Vienna) antibodies, with
peroxidase-derivatised secondary antibodies.
In vitro drug binding assays
Drug binding assays were performed with puri®ed N-terminal
htopoII domains and [3H]etoposide as described (25). Binding
ef®ciency is calculated as the ratio between [3H]etoposide and
[g-32P]ATP bound to the protein and normalised to 1 for the
wild-type domain. Assays were performed in the absence of
DNA, resulting in a low yield of ATP hydrolysis.
Drug sensitivity assays
Etoposide (VP16), teniposide (VM26), m-AMSA and
o-AMSA were from Sandoz Pharma AG (Basel,
Switzerland) or kind gifts of Dr Y. Pommier (NIH,
Bethesda, MD). For growth curves, yeast strains were cultured
in YPAD to saturation and diluted 2000-fold. After growth to
2±5 3 106/ml, cells were adjusted to 5 3 105/ml (65%,
veri®ed by counting) and distributed in triplicate into a 96-well
plate (135 ml/well) containing 15 ml of 10% DMSO or 10 mM±
2 mM drug in 10% DMSO. The microtitre plate was incubated
at 30°C for 3 h, then cell density was monitored at 660 nm
every 15 min over 16 h (Spectra MAX plus spectrophotometer;
Molecular Devices). The blank values were obtained by
mixing culture medium with the corresponding drug
concentration. All kinetics were determined multiple times.
Immuno¯uorescence
The indicated transformed yeast cells were grown overnight in
2% galactose and were harvested at a density of 2 3 107 cells/
ml. Immuno¯uorescence was performed by standard protocols
after pre-®xation (29) using monospeci®c primary antibodies
(af®nity puri®ed rabbit anti-ytopoII; see 28) and anti-nuclear
pore mAb414 (Berkeley Ab Co., Berkeley, CA). Detection
was on a Zeiss LSM 510 confocal microscope [100 3
PlanApo (NA = 1.4) objective], as previously described (29).
RESULTS
Mutations in the N-terminal domain of topoII enhance
drug sensitivity
We have previously shown that both the N-terminal and the
catalytic core domains of htopoIIa bind epipodophyllotoxins
in vitro (25). Guided by molecular modelling based on the
bacterial GyrB subunit, mutations K123A, V137W and E155F
were created at the predicted sites of contact between
etoposide and the ATP-binding cleft of the enzyme
(Fig. 1A). All three mutations reduce the drug binding
ef®ciency of a recombinant N-terminal domain (amino acids
1±440) in an in vitro binding assay, although they do not affect
the binding of ATP (Fig. 1B), con®rming that etoposide can
interact with the N-terminus of topoII. However, from our
modelling, we propose that etoposide ®ts in the upper part of
the cleft, impeding the free access of ATP instead of
substituting for ATP, as novobiocin does in GyrB. The
mutation we created in the Walker A motif (G164V) reduces
the af®nity of the domain for ATP, yet does not impair binding
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to radiolabelled etoposide (see 25) (Fig. 1B). The relative
af®nities of the mutated domains for VP16 and ATP are
summarised in Figure 1B. To examine the physiological
relevance of these observations, we next introduced these
mutations into the cDNA encoding the full-length htopoIIa
fused at its C-terminus to the epitope tags Myc and 6-His for
expression in budding yeast (Fig. 1A).
To study the in¯uence of these mutations on drug
sensitivity, the wild-type and mutated forms of htopoIIa
were expressed in a yeast strain lacking its endogenous
enzyme. It is known that the wild-type human enzyme can
complement the absence of yeast topoII (30) and that yeast
show sensitivity to etoposide (31). Increased drug resistance in
strains expressing the mutant forms might indicate that the
N-terminal binding site is indeed critical for trapping topoII in
a covalent complex with DNA. On the other hand, if drug
binding to the core domain is suf®cient for drug-induced
cytotoxicity, then the N-terminal mutations might have no
effect. A third possibility is that the two drug-binding sites
compete for a limited pool of etoposide. In this case, reducing
af®nity for the N-terminal binding site might render cells more
sensitive to a limited intracellular pool of etoposide, since drug
interaction with the catalytic core would be favoured. These
possibilities were tested by introducing plasmids encoding
either the wild-type or mutated form of htopoIIa into the
top2::LEU2 yeast strain GA559 (Materials and Methods and
Fig. 1C). During transformation, the essential TOP2 functions
are provided by pBB6 (CEN-URA3-S.c. TOP2), which is later
lost by plating cells on 5-FOA. The surviving populations
then express htopoIIa as the only source of topoII. In
these populations we could score the mutant forms for
complementation (30), as well as for altered drug resistance.
Figure 1. Wild-type and two mutated htopoIIa complement the absence of yeast topoII. (A) The wild-type and point mutated forms of full-length htopoIIa
cDNA were fused to c-Myc and 6-His epitope tags in a yeast expression vector (see Material and Methods). All constructs were sequenced to ensure that no
additional mutations were introduced. (B) Radiolabelled [3H]VP16 and [a-32P]ATP were used in a ligand binding assay performed in the presence of the indi-
cated recombinant wild-type and mutated N-terminal domains (amino acids 1±440) of htopoII, as previously described (25). The ratio of binding ef®ciencies
of both ligands was determined for each mutated form after each ef®ciency was normalised to the values obtained for the wild-type domain. (C) Individual
transformants of strain GA559 expressing the indicated mutated form of htopoIIa were streaked on selective media in the presence (±ura ±trp) or absence
(±trp +FOA) of pBB6, a URA3-based vector expressing wild-type yeast TOP2. Controls include this same top2::LEU2 strain transformed with the empty
vector pRS414 (±) or with vector pRS414 expressing wild-type htopoIIa (+). Growth is visible as a dark triangular patch. We see no dominant negative
effects from the expression of any of the htopoIIa proteins in yeast. Only the wild-type and the point mutants E155F and K123A are able to substitute for yeast
topoII to support mitotic growth in at least six of the eight colonies tested. (D) Full-length wild-type and the indicated mutant forms of htopoIIa are expressed
at equal levels, both in the presence (left panel) and in the absence (right panel) of the endogenous yeast topoII. Western blots were performed on whole cell
extracts of the indicated transformants using mouse anti-Myc (9E10) and rat anti-p42RNase H, an abundant cytosolic protein that serves as an internal standard.
The negative control strain (± control) carries an empty vector, while the positive control (+) expresses both yeast and human topoII enzymes.
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Western blot analysis of cells expressing both yeast and
human enzymes showed that the wild-type and mutated forms
of htopoIIa (a-Myc) are expressed equally and migrate with
the expected mobility (p42RNase H was used for normalisation;
Fig. 1D, left panel). None of the recombinant forms, wild-type
or mutant, had a dominant negative effect on cell growth (data
not shown). After shuf¯ing, we ®nd that the wild-type, the
K123A and the E155F forms of htopoIIa support mitotic growth
in yeast, while the ATP-binding site mutant, G164V, and the
V137W substitution do not (Fig. 1C). The non-viability of
these two mutants probably does not re¯ect insuf®cient
expression levels or misfolding of the human proteins in vivo,
as all are detected on western blots as full-length proteins and
their relative abundance suggests that they are as stable as the
wild-type enzyme (Fig. 1D). The G164V mutation in the ATP-
binding site has been shown previously to inactivate yeast
topoII (32) and would therefore account for the lack of
complementation. We speculate that the bulky tryptophan
substitution (V137W) may also interfere with ATP
turnover, although the mutated protein domain was able to
bind ATP (25).
Drug sensitivity of the viable top2::LEU2 yeast strains
expressing the wild-type, K123A or E155F forms of htopoIIa
was monitored by following growth rates in a 96-well plate in
the absence or presence of increasing drug concentrations (see
Materials and Methods). This automated procedure has been
shown to be an accurate and reliable means to compare the
effects of drugs on the growth of several strains in a single
experiment. Cell density was monitored at 660 nm for 16 h (an
example of the raw data is shown in Fig. 2A) and, to facilitate
comparisons, the optical density was plotted for each strain at
the optimal point in the growth curve (between 333 and
360 min; Fig. 2B±E) as a function of the drug concentration.
To ensure drug solubility, all assays were performed in 1%
DMSO, which alone has no effect in the growth rate assay
(data not shown). In the presence of increasing concentrations
of etoposide (VP16), we observed a decrease in cell growth
that was more severe for strains expressing mutant htopoIIa
than for those expressing the wild-type form (Fig. 2D). This
effect was similar for VM26, an etoposide-related inhibitor,
which is active at even lower concentrations (5±100 mM;
Fig. 2E). Plotting t1
2
max, the time at which cells reached half of
their maximal density, as a function of VM26 concentration
(Fig. 2F), con®rms that the K123A and E155F expressing strains
are signi®cantly more sensitive to epipodophyllotoxins
than the strain expressing wild-type htopoIIa. In contrast,
Figure 2. Drug sensitivity of top2::LEU2 yeast expressing the wild-type or mutated htopoIIa. Yeast growth is monitored in microtitre plates for 16 h in
increasing concentrations of the indicated drug, as described in Materials and Methods. (A) Typical examples of growth curve data obtained for strain GA559
expressing htopoIIa E155F in increasing concentrations of m-AMSA. (B±E) The OD660 for a given strain which was recorded at a ®xed time point (333 or
360 min as indicated) and is plotted as a function of increasing drug concentration [(B) m-AMSA; (C) o-AMSA; (D) VP16; (E) VM26] for the strains express-
ing the wild-type (diamond), K123A (square) or E155F (triangle) htopoIIa. The time point was chosen as being closest to half-maximal growth for the strain in
the absence of drug, but resulting graphs were similar between 300 and 500 min growth [see panel (A)]. (F) Time to half-maximal yeast density is plotted as
a function of VM26 concentration for strains expressing the wild-type, K123A or E155F form of htopoIIa. Error bars result from growth curves analysed in
triplicate. Each experiment was performed three times.
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increasing amounts of m-AMSA slowed growth of the wild-
type and the K123A mutants similarly and slightly more
ef®ciently for the E155F mutant (Fig. 2B). As expected, the
control compound, o-AMSA, had toxic effects only at very
high concentrations, and these were identical for all strains
tested (Fig. 2C). In conclusion, we ®nd that both mutants
E155F and K123A show enhanced sensitivity to the epipodo-
phyllotoxins VP16 and VM26, while only E155F is slightly
more sensitive to m-AMSA.
Overexpression of the N-terminal domain confers drug
resistance in yeast
The increased sensitivity to epipodophyllotoxins described
above could re¯ect either altered turnover rate or enhanced
expression levels of the mutated forms (19,33), yet we exclude
changes in protein levels by western blot analysis (see
Fig. 1D). On the other hand, since both the N-terminal
domain and the catalytic core can bind etoposide, this result
might alternatively re¯ect a competition for the drug between
the two domains in vivo. If true, mutated N-termini with lower
af®nity for etoposide should trap the drug less ef®ciently, thus
increasing the pool of etoposide available for binding near the
enzyme active site. To test this hypothesis, we expressed the
wild-type N-terminal domain of htopoIIa at high levels to see
if it is able to titrate the available drug and confer drug
resistance.
The wild-type and mutant N-terminal ATPase domains
were fused in-frame with the C-terminal 83 amino acids of
htopoIIa, which provide a NLS (Fig. 3A). These proteins are
tagged with c-Myc and 6-His epitopes and can be expressed in
the yeast strain GA1072 under control of the pGAL promoter.
As for the full-length enzymes, all forms are expressed to
equivalent levels and none has a dominant negative effect on
yeast growth in the absence of drug (Fig. 3B). To determine
the drug sensitivity of yeast cells expressing these N-terminal
domains, growth was analysed as described above and t1
2
max
was plotted as a function of etoposide concentration. Figure 3C
shows that cells overexpressing the wild-type N-terminal
domain are more resistant to etoposide than cells transformed
with the empty vector (Fig. 3C). This resistance was similar
for the G164V mutated domain, which binds VP16 but not
ATP, yet it is abolished by the E155F mutation and reduced by
the mutation K123A. The results indicate that the resistance
correlates well with the drug binding capacity of the
overexpressed fragment (Fig. 3C).
To interpret the variations in drug sensitivity, it was
important to quantify the levels of DNA topoII in yeast. To
this end, whole cell extracts were prepared after carefully
monitoring cell number and samples were western blotted
with an antibody raised against yeast topoII. Increasing
amounts of puri®ed yeast topoII of known concentrations
were loaded on the same gel for quanti®cation (Fig. 3D, right
panel). Considering the average radius of the G1 phase yeast
nucleus as 0.9 mm, we calculated a concentration of 15 mM for
the endogenous topoII. The same calculation was made to
quantify the intranuclear concentration of the human enzyme
expressed in the absence of yeast topoII. The reference protein
used in this case was the yeast silencing protein Sir2-6His
detected with an antibody raised against the penta-His antigen
(Fig. 3D, left panel). Here, the concentration of htopoIIa was
between 5 and 10 mM.
We also checked for mislocalisation of the N-terminal
domains and the endogenous ytopoII. Endogenous topoII
(detected by immuno¯uorescence) remains localised in the
nucleus, whether or not the small domain is expressed
(Fig. 4A). Overexpressed wild-type and mutated htopoIIa
domains are also exclusively nuclear and co-localise with the
yeast topoII, although quantitative western blots indicate that
the individual domains are expressed at >20-fold the level of
the full-length enzyme (Fig. 4B). Finally, fractionation assays
show that both the full-length htopoIIa and all the N-terminal
domains are associated with a chromatin fraction (data not
shown), suggesting that the ability of a domain to compete for
etoposide does not necessarily re¯ect its ability to associate
with chromatin.
DISCUSSION
We have previously characterised two distinct etoposide
binding sites in topoII in vitro. One was found within the
catalytic core, as suggested by other studies (23,27), while the
second was mapped to the N-terminal ATPase domain (25).
Several point mutations have been identi®ed within the ATP-
binding pocket of htopoIIa that lower the af®nity of the
domain for etoposide in vitro (25). However, because an
N-terminally truncated form of topoII is still capable of
forming the covalent cleavable complex with DNA in the
presence of drug (27) and because the Kd of etoposide binding
to the catalytic core domain is slightly lower than to the
N-terminal domain (25), it is likely that the binding site in the
core domain mediates the cytotoxic effects of the inhibitors.
As recently shown, each monomer of topoII binds the drug and
forms a cleavable complex with DNA independently of the
other (34).
Nonetheless, we ®nd that overexpression of the N-terminal
ATPase domain confers resistance to high concentrations of
etoposide in yeast. The phenotype does not result from the
ATPase activity of the N-terminal domain, because expression
of the G164V mutant, which binds etoposide but cannot use
ATP (25,32), confers the same resistance phenotype as the
wild-type domain. On the other hand, point mutations that
weaken etoposide binding in the N-terminal domain eliminate
the drug resistance. We propose that an excess of the topoII
N-terminal domain enhances drug resistance by competing
with the full-length enzyme for a limiting pool of inhibitor
(see Fig. 5A).
This model is consistent with other data showing that
enhanced drug resistance correlates with the expression of
topoII subfragments (reviewed in 6,19,20). In most of these
cases the subfragments remain in the cytoplasm, where they
do not directly interfere with topoII function in the nucleus,
but still appear to compete with nuclear topoII for the
inhibitor. This was true for a C-terminally truncated form of
yeast topoII, which was analysed in yeast (31). Similar topoII
mutations have been detected in drug-resistant human small
cell lung cancer cells (35±37).
When expressed as the unique source of topoII in yeast
cells, htopoIIa forms carrying point mutations in the ATPase
pocket (K123A and E155F) support mitotic growth as ef®ciently
as the wild-type enzyme, demonstrating that these mutant
forms are catalytically active. As shown above, they render
yeast more sensitive to epipodophyllotoxins, even though
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these mutations reduce the af®nity of the N-terminus for
etoposide in vitro. Hypersensitivity is not due to altered levels
of protein expression nor is it likely to re¯ect changes in the
catalytic activity of topoII. If it were, the cells would be
hypersensitive to all inhibitors that stabilise the cleavable
complex, yet we show here that the K123A mutation does not
render cells more sensitive to m-AMSA. Finally, both mutant
enzymes are equally active as the wild-type enzyme in yeast
cell extracts in vitro (data not shown).
To explain this, we propose that the ATP-binding cleft
competes for a limiting pool of drug even in the context of the
holoenzyme (Fig. 5). Under normal conditions, the catalytic
core domain of the DNA-bound topoII is probably the primary
target for topoII poisons that trigger cytotoxicity through
creation of DNA breaks. In this conformation, the ATPase
domain may not be able to bind the drug and would, instead,
ef®ciently bind and hydrolyse ATP (38). However, a
cytoplasmic or a nuclear, DNA-free population of topoII
should also be able to bind and sequester the drug, thereby
reducing the pool of free etoposide available to the active site
of the enzyme without inducing DNA damage (Fig. 5B).
When the N-terminal domain is mutated such that it binds
etoposide with a lower af®nity, then more inhibitor may be
available for the core domain, rendering cells more sensitive
Figure 3. Overexpression of the htopoIIa N-terminal domain confers drug resistance in yeast. (A) Scheme of the fusion between htopoIIa wild-type or
mutant N-terminal domains and the NLS. (B) Time required to reach half-maximal culture density (t1
2
max) was determined for the transformed yeast strain
GA1072, expressing the indicated htopoIIa N-terminal domains. The contents of eight microtitre wells of each transformant were analysed by western blotting
with antibodies against Myc or p42RNase H. (C) The increase in t1
2
max is shown as a function of VP16 concentration for GA1072 transformants expressing the
indicated htopoIIa N-terminal domain: no protein (diamond), N-term.NLS fusions wild-type (square), E155F (triangle), K123A (cross) and G164V (disc). Note
that GA1072 carries transporter mutations and is more sensitive to VP16 than normal yeast strains. The t1
2
max values in the absence of drug were normalised
to the strain carrying an empty vector. Error bars result from growth curves analysed in triplicate. Each experiment was performed three times. (D) The levels
of expression of both the human and the yeast topoII were analysed in yeast. The strains GA1659 (expressing only wild-type htopoIIa, left panel) and
GA1072 (expressing endogenous ytopoII, right panel) were grown and counted when harvested. Whole cell extracts were prepared and analysed by quantita-
tive western blotting with anti-pentaHis or anti-ytopoII antibodies, respectively. Increasing amounts of the yeast transcription regulator Sir2-6His and yeast
topoII, both puri®ed to homogeneity, were used as standards for the quanti®cation. * indicates a non-speci®c signal obtained with the antibody raised against
ytopoII.
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to a given concentration of drug (Fig. 5C). The modulation of
drug sensitivity through this mechanism is plausible only if
intracellular drug concentrations are quite low. This appears to
be the case in yeast, as it was previously found that low level
expression of intact topoII or of cytoplasmically localised
subfragments of the enzyme correlates with enhanced drug
resistance (31). Moreover, to be valid, the model we propose
requires an effective drug concentration that is not in vast
excess as compared to the yeast endogenous topoII concen-
tration. The concentrations of 15 and 5±10 mM found,
respectively, for the endogenous ytopoII and for the htopoII
expressed in yeast after shuf¯ing is slightly lower than 40 mM,
the concentration of drug shown to produce a signi®cant
difference in drug sensitivity in vivo (Figs 2 and 3). However,
these values are within the same range. Moreover, the
concentration of the drug added extracellularly is certainly
higher than the effective intracellular concentration. Indeed,
yeast drug ef¯ux pumps and non-speci®c interactions with
intracellular structures are mechanisms that decrease the
concentration of free drug available to topoII in the nucleus.
Importantly, the effective drug concentration is very close to
the dissociation constants found for the drug binding sites
(20 mM for the N-terminal domain and the full-length enzyme
and 9 mM for the catalytic core domain) (25).
Our data are consistent with studies reporting mutations in
the ATP-binding domain of topoII that affect drug sensitivity
and provide evidence that the ATPase domain of topoII can
bind at least some topoII inhibitors in vivo. However, in
Figure 4. Highly overexpressed htopoIIa N-terminal domains localise to the yeast nucleus. (A) After 16 h induction, cells expressing the indicated htopoIIa
N-terminal domain or carrying an empty vector were formaldehyde ®xed and immunostained for ytopoII (af®nity puri®ed atopoII antibody is visualised in
green) and for the htopoIIa domains (a-Myc, visualised in red). Co-localisation is shown in yellow. Insets show reactions in the absence of primary anti-
bodies. Where indicated, the nuclear envelope is detected with mAb414 (a-pore, in red). (B) The level of overexpression of the htopoIIa N-terminal domains
was determined in a strain expressing full-length wild-type htopoIIa from a single copy plasmid. Both constructs carry a single c-Myc epitope, which allows
direct comparison of the relative levels of overexpression. Quantitation indicates at least 20-fold excess of the small domains over full-length protein.
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contrast to novobiocin for GyrB (26) and bisdioxopiperazine
for topoII (24), we consider that the site of interaction of
etoposide within the ATP-binding domain of the enzyme does
not necessarily represent the key mechanism of action of this
drug, but rather a secondary interaction site that modi®es the
effectiveness of antitumour agents. Useful paradigms for
future drug development may well rest upon the observation
that both intra- and intermolecular competition can modulate
epipodophyllotoxin-mediated cytotoxicity.
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